Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: Experience of the Eastern Cooperative Oncology Group

Journal of Clinical Oncology

Volumn 17, Issue 6, 1999, Pages 1689-1700

  Recht, Abram ^a   Gray, Robert ^a   Davidson, Nancy E ^a   Fowble, Barbara L ^a   Solin, Lawrence J ^a   Cummings, Frank J ^a   Falkson, Geoffrey ^a   Falkson, Hendrika C ^a   Taylor IV, Samuel G ^a   Tormey, Douglass C ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MENOPAUSE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TUMOR VOLUME;

EID: 0033063501     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.6.1689     Document Type: Article

References (59)

1. Cuzick J, Stewart H, Rutqvist L, et al: Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol 12:447-453, 1994
2. Recht A: The return (?) of postmastectomy radiotherapy. J Clin Oncol 13:2861-2864, 1995 (editorial)
3. Harris JR, Morrow M: Local management of invasive breast cancer, in Harris JR, Lippman ME, Morrow M, et al (eds): Diseases of the Breast. Philadelphia, PA, Lippincott, 1996, pp 485-545
4. Early Breast Cancer Trialists' Collaborative Group: Effects of radiotherapy and surgery in early breast cancer: An overview of the randomized trials. N Engl J Med 333:1444-1455, 1995
5. Pierce LJ, Lichter AS: Defining the role of post-mastectomy radiotherapy: The new evidence. Oncology (Huntingt) 10:991-1002, 1996
6. Fowble B: Postmastectomy radiotherapy: Then and now. Oncology (Huntingt) 11:213-239, 1997
7. Overgaard M, Hansen PS, Overgaard J, et al: Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med 337:949-955, 1997
8. Ragaz J, Jackson SM, Le N, et al: Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 337:956-962, 1997
9. Fowble B, Gray R, Gilchrist K, et al: Identification of a subgroup of patients with breast cancer and histologically positive axillary nodes receiving adjuvant chemotherapy who may benefit from postoperative radiotherapy. J Clin Oncol 6:1107-1117, 1988
10. Tormey DC, Gray R, Gilchrist K, et al: Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-flouorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients: An Eastern Cooperative Oncology Group trial. Cancer 65:200-206, 1990
11. Taylor SG, Knuiman MW, Sleeper LA, et al: Six-year results of the Eastern Cooperative Oncology Group trial of observation versus CMFP versus CMFPT in postmenopausal patients with node-positive breast cancer. J Clin Oncol 7:879-889, 1989
12. Falkson HC, Gray R, Wolberg WH, et al: Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: An Eastern Cooperative Oncology Group phase III study. J Clin Oncol 8:599-607, 1990
13. Tormey DC, Gray R, Abeloff MD, et al: Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: An Eastern Cooperative Oncology Group trial. J Clin Oncol 10:1848-1856, 1992
14. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, John Wiley and Sons, 1980
15. Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
16. Snedecor GW, Cochran WG: Statistical Methods (ed 6). Ames, IA, Iowa State University Press, 1967
17. Mehta CR, Patel HR: A network of algorithm for performing Fisher's exact test in R X C contingency tables. J Am Stat Assoc 78:427-434, 1983
18. Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc (in press)
19. Recht A, Hayes DF, Eberlein TJ, et al: Local-regional recurrence after mastectomy or breast-conserving therapy, in Harris JR, Lippman M, Morrow M, et al (eds): Diseases of the Breast. Philadelphia, PA, Lippincott, 1996, pp 649-667
20. Ahmann DL, O'Fallon JR, Scanlon PW, et al: A preliminary assessment of factors associated with recurrent disease in a surgical adjuvant clinical trial for patients with breast cancer with special emphasis on the aggressiveness of therapy. Am J Clin Oncol 5:371-381, 1982
21. McArdle CS, Crawford D, Dykes EH, et al: Adjuvant radiotherapy and chemotherapy in breast cancer. Br J Surg 73:264-266, 1986
22. Vélez-García E, Carpenter JT, Moore M, et al: Postsurgical adjuvant chemotherapy with or without radiotherapy in women with breast cancer and positive axillary nodes: A South-Eastern Cancer Study Group (SEG) trial. Eur J Cancer 28A: 1833-1837, 1992
23. Tennvall-Nittby L, Tenegrup I, Landberg T: The total incidence of loco-regional recurrence in a randomized trial of breast cancer TNM stage II: The South Sweden Breast Cancer Trial. Acta Oncol 32:641-646, 1993
24. Goldhirsch A, Gelber RD, Castiglione M: Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: Patterns and prognoses. J Clin Oncol 6:89-97, 1988
25. Buzdar A, McNeese MD, Hortobagyi GN, et al: Is chemotherapy effective in reducing the local failure rate in patients with operable breast cancer? Cancer 65:394-399, 1990
26. Kaufmann M, Jonat W, Abel U, et al: Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer. J Clin Oncol 11:454-460, 1993
27. Chu AM, Kiel K: Comparison of adjuvant postoperative radiotherapy and multiple-drug chemotherapy (CMF-VP) in operable breast cancer patients with more than four positive axillary lymph nodes. Cancer 50:212-218, 1982
28. Gelman R, Gelber R, Henderson IC, et al: Improved methodology for analyzing local and distant recurrence. J Clin Oncol 8:548-555, 1990
29. Caplan RJ, Pajak TF, Cox JD: Analysis of the probability and risk of cause-specific survival. Int J Radiat Oncol Biol Phys 29:1183-1186, 1994
30. Schulgen G, Schmoor C, Sauerbrei W, et al: A note on estimating local recurrence rates in clinical trials on the treatment of breast cancer. Breast Cancer Res Treat 49:87-91, 1998
31. Sykes HF, Sim DA, Wong CJ, et al: Local-regional recurrence in breast cancer after mastectomy and Adriamycin-based adjuvant chemotherapy: Evaluation of the role of postoperative radiotherapy. Int J Radiat Oncol Biol Phys 16:641-647, 1989
32. Pisansky TM, Ingle JN, Schaid DJ, et al: Patterns of tumor relapse following mastectomy and adjuvant systemic therapy in patients with axillary lymph node-positive breast cancer. Cancer 72:1247-1260, 1993
33. Diab SG, Hilsenbeck SG, deMoor CA, et al: Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy. J Clin Oncol 16:1655-1660, 1998
34. O'Rourke S, Galea MH, Morgan D, et al: Local recurrence after simple mastectomy. Br J Surg 81:386-389, 1994
35. Bijker N, Rutgers EJT, Peters JL, et al: Modified radical mastectomy or how to achieve optimal loco-regional control in larger breast cancers. Eur J Surg Oncol 20:258, 1994 (abstr)
36. Stal O, Sullivan S, Wingren S, et al: c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer 31A:2185-2190, 1995
37. Zellars RC, Clark GM, Allred DC, et al: Prognostic value of p53 for local failure in mastectomy treated breast cancer patients. Proc Am Soc Clin Oncol 17:104a, 1998 (abstr 401)
38. Ahlborn TN, Gump FE, Bodian C, et al: Tumor to fascia margin as a factor in local recurrence after modified radical mastectomy. Surg Gynecol Obstet 166:523-526, 1988
39. Mentzer SJ, Osteen RT, Wilson RE: Local recurrence and the deep resection margin in carcinoma of the breast. Surg Gynecol Obstet 163:513-517, 1986
40. Freedman GM, Fowble BL, Hanlon AL, et al: A close or positive margin after mastectomy is not an indication for chest wall irradiation except in women aged fifty or younger. Int J Radiat Oncol Biol Phys 41:599-605, 1998
41. Fisher B, Redmond C, Wicherham DL, et al: Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol 7:572-582, 1989
42. Muss HB, Cooper MR, Brockschmidt JK, et al: A randomized study of chemotherapy (L-PAM vs CMF) and irradiation for node positive breast cancer: Eleven year follow-up of a Piedmont Oncology Association trial. Breast Cancer Res Treat 19:77-84, 1991
43. Fisher B, Brown AM, Dimitrov NV, et al: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8:1483-1496, 1990
44. Budd GT, Green S, O'Bryan RM, et al: Short-course FAC-M versus 1 year of CMFVP in node-positive, hormone receptor-negative breast cancer: An Intergroup study. J Clin Oncol 13:831-839, 1995
45. Levine M, Bramwell VH, Pritchard KI, et al: Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. J Clin Oncol 16:2651-2658, 1998
46. Moliterni A, Bonadonna G, Valagussa P, et al: Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes. J Clin Oncol 9:1124-1130, 1991
47. Fisher B, Anderson S, Wickerham DL, et al: Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from the National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 15:1858-1869, 1997
48. Peters WP, Ross M, Vrendenburgh JJ, et al: High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11:1132-1143, 1993
49. International Breast Cancer Study Group: Late effects of adjuvant oophorectomy and chemotherapy upon premenopausal breast cancer patient. Ann Oncol 1:30-35, 1990
50. Dombernowsky P, Hansen M, Mouridsen HT, et al: Randomized trial of adjuvant CMF + radiotherapy (RT) vs CMF a lone vs CMF + tamoxifen (TAM) in pre-and menopausal stage II breast cancer. Eur J Cancer 30A:S28, 1994 (suppl 2) (abstr)
51. Overgaard M, Hansen PS, Overgaard J, et al: Randomized trial evaluating postoperative radiotherapy in high-risk postmenopausal breast cancer patients given adjuvant tamoxifen: Results from the DBCG 82c trial. Radiother Oncol 48:S78, 1998 (suppl 1) (abstr)
52. Boccardo F, Rubagotti A, Amoroso D, et al: Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients: An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-hormone Therapy Cooperative Group) Trial. Eur J Cancer 28:673-680, 1992
53. Boccardo F, Rubagotti A, Bruzzi P, et al: Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: Results of a multicentric Italian trial. J Clin Oncol 8:1310-1320, 1990
54. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 351:1451-1467, 1998
55. Maddox W, Carpenter J, Laws H: A randomized prospective trial of radical mastectomy versus modified radical mastectomy in 311 breast cancer patients. Ann Surg 198:207-212, 1983
56. Turner L, Swindell R, Bell W, et al: Radical versus modified radical mastectomy for breast cancer. Ann R Coll Surg Engl 63:239-243, 1981
57. Recht A, Houlihan MJ: Axillary lymph nodes and breast cancer: A review. Cancer 76:1491-1512, 1995
58. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomized trials. Lancet 352:930-942, 1998
59. Recht A, Bartelink H, Fourquet A, et al: Postmastectomy radiotherapy: Questions for the twenty-first century. J Clin Oncol 16:2886-2889, 1998